Meningococcal Vaccination Among Adolescents in the United States: A Tale of Two Age Platforms

Kurosky, Samantha; Esterberg, Elizabeth; Irwin, Debra E.; Trantham, L; Packnett, Elizabeth; Novy, Patricia; Whelan, Jane; Hogea, Cosmina

doi:10.1016/j.jadohealth.2019.02.014

Cited by 12 publications

(35 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, simultaneous vaccination is an effective measure to increase vaccine uptake and shows the usefulness of adolescent and adult vaccination platforms. [51][52][53] Study limitations Many of the selected studies had only a limited description of the epidemiological profile of pertussis among adolescents, adults, and older adults. However, the results to the least suggest the disease prevalence among adolescents and adults is sufficient to perpetuate the circulation of B. pertussis, as they serve as a reservoir for the pathogen, thus placing young children at permanent risk of developing pertussis and suffering the consequences of the disease.…”

Section: Some Evidence Of Pertussis In Adults Outside Latin Americamentioning

confidence: 99%

Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review

Nunes

Abreu

Furtado

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

We aimed to describe the impact of pertussis on adolescents, adults, and older adults over 2007-2018 in selected Latin American countries by reviewing the literature. We searched the Medline, Embase, Scopus, LILACS, Scielo, Google Scholar, CAPES Journals Web-portal, and Cochrane databases for observational epidemiological studies, clinical trials, and systematic reviews of primary studies. Data were extracted and analyzed for all individuals aged ≥10 years. Of 6,891 studies identified only 25 were eligible. Studies were conducted in Brazil (14), Argentina (4), Colombia (4), Mexico (2) and Chile (1). Epidemiological data among target population were limited. No studies clearly assessed the status of asymptomatic or oligosymptomatic B. pertussis carriers in these age groups. Among all pertussis cases identified, the percentage of patients ≥10 years-old ranged between 2.1% and 66.7% depending on country and sample characteristics. The definition of cases, diagnostic methods, and age groups were not consistent across studies.

show abstract

Section: Some Evidence Of Pertussis In Adults Outside Latin Americamentioning

confidence: 99%

Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review

Nunes

Abreu

Furtado

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…18,19 A recent analysis suggested that the lower rates of MenACWY uptake between younger (72%) and older adolescents (49%) is partially driven by fewer preventive health-care visits among older adolescents. 20 Another analysis found that recent health-care visits were associated with receipt of the second dose at age 17 y. 21 While health-care utilization is clearly essential for vaccination, the lack of visits by older adolescents does not fully explain low coverage.…”

Section: Patient Factorsmentioning

confidence: 99%

“…21 In another study, a greater proportion of older adolescents (32%) had missed opportunities for MenACWY vaccination than did younger adolescents (22%). 20 These missed opportunities may be related to provider and practice factors, discussed below.…”

Section: Patient Factorsmentioning

confidence: 99%

Suboptimal uptake of meningococcal vaccines among older adolescents: Barriers, solutions, and future research directions

Niccolai

Hansen

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Over the past 15 y, several vaccines have been added to the recommended immunization schedule for adolescents in the United States. In addition to annual influenza vaccination, the Advisory Committee on Immunization Practices recommends tetanus, diphtheria, and pertussis (Tdap), meningococcal conjugate (MenACWY), and human papillomavirus (HPV) vaccine for routine administration at ages 11-12 y, and a second dose of MenACWY at age 16. A vaccine against meningococcal disease caused by serogroup B (MenB) is also available and recommended for shared clinical decision-making. Though notable gains in uptake have been achieved for some adolescent vaccines, coverage varies considerably with lower rates for HPV vaccine and second dose of MenACWY. Coverage for MenB is especially low. While extensive research has focused on barriers to and solutions for higher uptake of HPV vaccine, limited attention has been given to the reasons for lower uptake of meningococcal vaccines among older adolescents. This purpose of this commentary is to discuss barriers to and solutions for higher uptake of meningococcal vaccines among older adolescents, and to identify gaps in knowledge that can inform research efforts going forward.

show abstract

“…In this issue of the Journal of Adolescent Health, Kurosky et al [12] report findings on MenACWY uptake among adolescents using Marketscan commercial and Medicaid claims data, demonstrating that uptake among older adolescents (defined as those aged 15.5 through 18 years) is lower than that of younger adolescents (10.5 through 13 years). Although receipt of the primary versus booster dose among older adolescents could not be distinguished in this analysis, these findings are likely consistent with National Immunization SurveyeTeen data demonstrating low booster dose uptake.…”

mentioning

confidence: 99%

“…This article from Kurosky et al [12] provides additional insight into the unique challenges in vaccinating older adolescents against a now very uncommon, yet among the most feared, infectious disease. Through awareness of meningococcal vaccine recommendations and making use of every opportunity to ensure that both the MenACWY primary and booster doses have been administered, providers can help ensure that the gains achieved in reducing meningococcal disease burden in the past 14 years since the vaccine first became available are sustained.…”

mentioning

confidence: 99%

Meningococcal Conjugate Vaccine in the United States: Remaining Challenges for Adolescent Vaccination

Mbaeyi

Stokley

2019

Journal of Adolescent Health

View full text Add to dashboard Cite

Meningococcal Vaccination Among Adolescents in the United States: A Tale of Two Age Platforms

Cited by 12 publications

References 19 publications

Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review

Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review

Suboptimal uptake of meningococcal vaccines among older adolescents: Barriers, solutions, and future research directions

Meningococcal Conjugate Vaccine in the United States: Remaining Challenges for Adolescent Vaccination

Contact Info

Product

Resources

About